Spirulina and autoimmune disease: the NK stimulation concern, NOX2 benefit, and condition-specific guidance

The two opposing mechanisms

Immunostimulatory effects: Spirulina polysaccharides (calcium spirulan, immulina) activate NK cells and stimulate IL-12 production from macrophages and dendritic cells. NK cells kill infected and abnormal cells and activate the adaptive immune system via IFN-γ secretion. This is the mechanism by which spirulina enhances resistance to infection — and also the mechanism that conflicts with immunosuppressive therapies used in autoimmune disease.
Anti-inflammatory effects: Phycocyanobilin inhibits NADPH oxidase (NOX2) in neutrophils, macrophages, and endothelial cells. NOX2-derived superoxide activates NF-κB, which drives IL-6, TNF-α, IL-1β, and BAFF production across autoimmune conditions. Phycocyanobilin disrupts this amplification loop. This effect is directionally anti-inflammatory and potentially beneficial in autoimmune conditions characterised by oxidative inflammatory amplification.

Organ transplant: Tacrolimus/ciclosporin/mycophenolate regimens suppress NK cells to prevent rejection. Spirulina’s NK stimulation directly opposes this. Avoid without transplant specialist review.
ANCA-associated vasculitis on rituximab or cyclophosphamide: Induction therapy requires deep immunosuppression. Spirulina is not appropriate during induction phase. Maintenance phase on reduced immunosuppression: discuss with rheumatologist.
Active lupus nephritis on mycophenolate or cyclophosphamide: Same concern as vasculitis induction. Defer to rheumatologist.
Autoimmune POI, autoimmune hepatitis, myositis on high-dose corticosteroids: The immunosuppression level is significant; NK stimulation requires specialist discussion.

Rheumatoid arthritis on biologics (TNF inhibitors, IL-6 inhibitors, JAK inhibitors): Biologics reduce immunosurveillance. Spirulina NK stimulation is directionally opposed. In practice, many RA patients on TNF inhibitors take spirulina without documented adverse outcomes — but formal guidance supports rheumatologist discussion.
Sjögren’s, myositis, scleroderma on azathioprine or low-dose mycophenolate: The immunosuppression is less profound than induction doses; risk is lower but not absent. Discuss with rheumatologist.

Rheumatoid arthritis on methotrexate + hydroxychloroquine only (no biologics): Methotrexate and HCQ are not deep immunosuppressants. NK stimulation concern is lower. 3–5 g/day with rheumatologist awareness is reasonable.
Psoriasis on topical therapy or methotrexate only: NK stimulation concern is low. Phycocyanobilin’s NF-κB inhibition may benefit the keratinocyte inflammatory cycle.
Hashimoto’s thyroiditis (euthyroid, on levothyroxine only): No systemic immunosuppression. NK stimulation concern is low. NOX2 inhibition in thyroid follicular cells may reduce ongoing glandular damage.
Mild PCOS, non-autoimmune coeliac disease (GFD-compliant): No immunosuppression concerns. Standard 3–5 g/day dose.

Rule 1 — Always inform: Tell your rheumatologist, immunologist, or specialist that you take or want to take spirulina. Even in lower-risk conditions, transparency allows proper assessment.
Rule 2 — Assess the immunosuppression depth: The deeper the immunosuppression (induction > maintenance biologic > DMARD only > topical/HCQ only), the greater the NK stimulation concern. Adjust accordingly.
Rule 3 — Assess disease activity: Active flare on induction therapy > defer. Stable remission on low-maintenance immunosuppression > lower risk, but still discuss.
Rule 4 — Start low if approved: 1–2 g/day initially, increasing over 2–4 weeks; monitor for any flare or change in disease markers.

Anaemia of chronic disease (ACD) is common across autoimmune conditions. IL-6-driven hepcidin production restricts iron availability despite adequate stores. Ferritin is an acute-phase reactant and is often elevated in active disease even when iron is functionally depleted.
Use transferrin saturation (<20%) and reticulocyte haemoglobin content to assess true iron deficiency in active autoimmune disease. Spirulina’s modest non-haem iron is not sufficient to correct ACD; the primary treatment is controlling disease activity to reduce hepcidin.